PRAX: financial statements from SEC — TradeAlmanac

PRAX

Praxis Precision Medicines, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Revenue	—	0	0	0	—	302,000	357,000
Research and development	78m	66m	63m	61m	—	42m	27m
Selling, general and administrative	28m	13m	13m	14m	—	15m	11m
Operating expenses	106m	78m	76m	75m	—	57m	38m
Operating income	−106m	−78m	−76m	−75m	—	−57m	−37m
Net income	−93m	−74m	−71m	−69m	−59m	−52m	−33m
Earnings per share	−3.20	−3.36	−3.31	−3.29	—	−2.75	−1.74
Earnings per share, diluted	−3.20	−3.36	−3.31	−3.29	—	−2.75	−1.74
Weighted average shares	29m	22m	21m	21m	—	19m	19m
Weighted average shares, diluted	29m	22m	21m	21m	—	19m	19m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	536m	357m	150m	157m	166m	215m	169m	145m
Short-term investments	251m	242m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−86m	−53m
Depreciation and amortisation	39,000	47,000
Share-based compensation	17m	9m
Capital expenditure	62,000	0
Investing cash flow	−344m	−51m
Financing cash flow	609m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)